Sectors ETFs Today Universe Correlation Playbook Watchlists Portfolios News Alerts Research Bots About

Daily digest

One email a day · alerts + bubble shifts · free during beta.

About Alerts Research Support ♡Disclosures Terms Privacy FR PT API Follow on X

US equities · Daily close · Refreshed nightly 22:30 Paris

Not investment advice. QuantAbundancia is educational research only. Nothing on this site is a recommendation to buy, sell, or hold any security. Past performance does not guarantee future results. Full disclosures.

We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.

News

High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

3,483 signal articles · 326 in last 24h · 15,221 total before filter · latest 12m ago

326last 24h

1831last 7d

326🟢 bullish (7d)

187🔴 bearish (7d)

130publishers

All 🌍 Macro268 📊 Earnings929 🤝 M&A79 ⚖️ Regulatory20 🚀 Product14 📈 Analyst21

✕ clear all filtersticker: TMDXSentiment:bullish neutral bearish ✓ showing all (incl. clickbait)

GuruFocus.com5d agoneutral

TransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...

TransMedics Group Inc (TMDX) reports a 21% revenue increase while navigating regulatory impacts and competitive pressures.

TMDX

Zacks7d agobearish

TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall

TransMedics' Q1 revenues rise 21% on strong OCS demand, but a sharp EPS miss and margin pressure send shares down despite continued logistics growth.

TMDX

Motley Fool7d agoneutral

TransMedics (TMDX) Q1 2026 Earnings Transcript

Waleed Hassanein: Thank you so much, Hannah. As always, joining me today is Gerardo Hernandez, our Chief Financial Officer. Since inception, TransMedics has been relentless in our pursuit to transform organ transplant therapy by increasing utilization of donor organs and improving the clinical outcomes of transplant patients throughout -- through technology and service innovation and by disrupting the status quo.

TMDX

Moby7d agoneutral

TransMedics Group, Inc. Q1 2026 Earnings Call Summary

Moby summary of TransMedics Group, Inc.'s Q1 2026 earnings call

TMDX

MarketBeat7d agoneutral

TransMedics Group Q1 Earnings Call Highlights

TransMedics Group (NASDAQ:TMDX) reported first-quarter 2026 revenue of $174 million, up about 21% year over year and 8% sequentially, as the company continued to expand adoption of its Organ Care System (OCS) platform and its National OCS Program (NOP) logistics model while increasing investment in

TMDX

Zacks7d agoneutral

TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

TMDX

Zacks7d agobearish

TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of -51.46% and -0.99%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TMDX